- COBENFY™ (xanomeline and trospium chloride) for Schizophrenia
COBENFY™ (xanomeline and trospium chloride) is an oral pill used for the treatment of schizophrenia in adults See indication and Important Safety Information
- Cobenfy for Schizophrenia: Uses, Side Effects, Dosage
Cobenfy (xanomeline and trospium chloride) is a new treatment for schizophrenia used to improve positive and negative symptoms Cobenfy contains xanomeline, which helps schizophrenia symptoms, and trospium, which works to reduce the side effects
- Cobenfy: A New Treatment Option for Schizophrenia - WebMD
Cobenfy (xanomeline-trospium chloride) was approved for the treatment of adults with schizophrenia in 2024 Cobenfy is the first medicine approved for the treatment of schizophrenia that works
- Cobenfy: Uses, Side Effects, Dosage, How to Take, Cost, and More
Cobenfy (xanomeline trospium chloride) is a prescription oral capsule that treats schizophrenia in adults Learn about dosage, side effects, and more
- 3 Things to Know About Cobenfy, the New Schizophrenia Drug
Antipsychotic drugs that target dopamine directly have been given to patients with schizophrenia in the form of pills, liquids, and injections since the 1950s Cobenfy is the first of what could potentially be several new medications that target receptors in the brain other than dopamine
- With site ‘irregularities,’ BMS delays key Cobenfy readout
With site ‘irregularities,’ Bristol Myers delays key Cobenfy readout in Alzheimer’s psychosis By Angus Liu Dec 3, 2025 10:14am Bristol Myers Squibb Cobenfy Alzheimer's disease clinical trial
- Cobenfy as an Adjunctive Agent in Schizophrenia: Peter J. Weiden, MD . . .
Bristol Myers Squibb announces topline results from phase 3 ARISE trial evaluating Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia
- Cobenfy (Xanomeline-Trospium Chloride): A New Frontier in Schizophrenia . . .
Recently, Cobenfy, a novel antipsychotic combining xanomeline and trospium chloride, received the United States (US) Food and Drug Administration (FDA) approval, marking a significant advancement in schizophrenia treatment
|